Community Spotlight

Feb2018 AlzheimersInDs 637297080437914151 o6UI7E

Research News Community Spotlight Research Spotlight

LuMind IDSC statement on FDA Advisory Committee for promising Alzheimer’s drug, donanemab

LuMind IDSC is encouraged by today’s news that the U.S. Food and Drug Administration (FDA)…

Kate O’NeillMarch 8, 2024

Community Spotlight Research Spotlight

Message from the CEO: a look ahead to 2024

“I want to enjoy my life for a long time. I want to grow old…

Kate O’NeillJanuary 18, 2024

Community Spotlight

Progress in 2023 – our annual impact report

Thanks to the extraordinary support and engagement of the Down syndrome community, LuMind IDSC is…

Kate O’NeillDecember 21, 2023

Research News Community Spotlight

Reuters Article: Barriers to Latest Alzheimer’s Treatments for Down Syndrome Community

Hampus Hillerstrom, CEO of LuMind IDSC Foundation and father to a child with Down syndrome,…

Shannon BergstresserNovember 14, 2023

Community Spotlight

LuMind IDSC names new Director of Community Programs

Following a five-month, national search, LuMind IDSC Down Syndrome Foundation announced the appointment of Christina…

Kate O’NeillSeptember 21, 2023

Community Spotlight Research News Research Spotlight

Boston Globe OpEd People with Down Syndrome Now Left Out of Treatment

LuMind IDSC and The Arc of Northeast collaborated on an OpEd that was recently published…

Kate O’NeillSeptember 18, 2023

Community Spotlight Research News

Key updates on Down syndrome community access to new Alzheimer’s drugs

Five takeaways for the Down syndrome community: Updates on accessing the new Alzheimer’s drugsLuMind IDSC…

Kate O’NeillJuly 7, 2023

Community Spotlight

Meet the Black Down Syndrome Association

by guest contributor, Crystal Lotterberry, co-founder of the Black Down Syndrome Association About the Black…

Kate O’NeillJuly 7, 2023

Community Spotlight

LuMind IDSC joins Advocacy Day on Capitol Hill

In April, leaders from LuMind IDSC joined with 350 self-advocates, caregivers, and professionals to meet…

Kate O’NeillMay 12, 2023

Research Spotlight Community Spotlight

Hope and Action for Down syndrome Alzheimer’s research on WDSD 2023

Each year, the Down syndrome community and our supporters – family, friends, businesses, organizations and…

Kate O’NeillMarch 21, 2023

LuMind IDSC statement on FDA Advisory Committee for promising Alzheimer’s drug, donanemab

Message from the CEO: a look ahead to 2024

Progress in 2023 – our annual impact report

Reuters Article: Barriers to Latest Alzheimer’s Treatments for Down Syndrome Community

LuMind IDSC names new Director of Community Programs

Boston Globe OpEd People with Down Syndrome Now Left Out of Treatment

Key updates on Down syndrome community access to new Alzheimer’s drugs

Meet the Black Down Syndrome Association

LuMind IDSC joins Advocacy Day on Capitol Hill

Hope and Action for Down syndrome Alzheimer’s research on WDSD 2023

Recent Posts

CONTACT LUMIND IDSC

QUICK LINKS

NEED MORE INFORMATION?